Abstract:ID 90764 Poster Board 476 Migraine is the most common neurological disorder in the world, and is characterized by severe headaches, nausea, and light sensitivity. Current migraine treatments, including opioids and triptans, produce dangerous and uncomfortable side effects. Moreover, modern anti-migraine drugs lack novel mechanisms of action, often resulting in side effects similar to traditional approaches. Our aim is to revolutionize migraine pain management by finding new medications with novel mechanisms that can provide relief from migraine without causing any negative side effects. Fatty acid amide hydrolase (FAAH) and soluble epoxide hydrolase (sEH) are two pain-related enzymes. The potential benefits of dual-enzyme inhibitors include fewer drug-to-drug interactions and improved drug synergism compared to the administration of just one enzyme inhibitor. Importantly, these dual inhibitors may require lower doses than the traditional anti-migraine agent, sumatriptan. We hypothesized that simultaneous inhibition of FAAH and sEH using a dual sEH/FAAH inhibitor will alleviate migraine-related pain in rats. We previously identified a potent dual inhibitor SW-17 with IC 50 values of 9.8 nM and 2.5 nM in human FAAH and human sEH enzymes, respectively. Interestingly, SW-17 was significantly less active in mouse sEH, but was very potent in rat sEH with IC50 value of 3.9 nM. In this study, we synthesized 19 follow-up analogs of SW-17 to test the importance of the sulfonamide group. After evaluation of their potencies at inhibiting human, mouse, and rat enzymes, it appears that SW-17 is the most potent dual inhibitor; therefore, SW-17 was scaled up and evaluated in vivo . In migraineurs, an injection of nitroglycerin typically triggers a migraine attack, which makes it a useful tool to generate headache-like pain in animals. An injection of nitroglycerin produces hypersensitivity in periorbital and hindpaw regions. Thus, we investigated the effects of various doses of dual inhibitors of sEH and FAAH in a rat model of nitroglycerin-induced pain to assess its efficacy. To induce migraine pain, we injected 10 mg/kg nitroglycerin, a vasodilator that induces migraine-like pain. Thirty minutes prior to the injection of nitroglycerin, we pre-treated rats with a dose of SW-17, the sEH/FAAH dual inhibitor, in varying doses (0.1, 0.3, and 1 mg/kg) or sumatriptan. Mechanical thresholds in the hindpaw were assessed 30, 60, and 120 minutes after nitroglycerin injection. A nitroglycerin injection lowered sensory thresholds in female rats indicating migraine-like pain. A pre-treatment of SW-17 and sumatriptan prevented nitroglycerin-induced decreases in mechanical hypersensitivity. Finally, a wheel running test indicated that SW-17 does not decrease voluntary activity in rats indicating that this drug may not produce motoric side effects. Future studies will determine the full efficacy of FAAH and sEH inhibition in alleviating migraine-like pain in rats. Funded by NIH grant R16 GM150781 and CSUBIOTECH.

4-Phenyl-thiazole-based dual inhibitors of fatty acid amide hydrolase and soluble epoxide hydrolase do not alleviate orofacial inflammatory pain in female rats

Multitarget-Directed Ligands with Soluble Epoxide Hydrolase and Fatty Acid Amide Hydrolase Inhibitory Activities for Treatment of Chronic Pain

Simultaneous Inhibition of Soluble Epoxide Hydrolase and Fatty Acid Amide Hydrolase Prevents Nitroglycerin-induced Hypersensitivity in Female Rats

Design and Potency of Dual Soluble Epoxide Hydrolase/Fatty Acid Amide Hydrolase Inhibitors

Inhibition of the Soluble Epoxide Hydrolase as an Analgesic Strategy: A Review of Preclinical Evidence

Structure-guided discovery of potent and oral soluble epoxide hydrolase inhibitors for the treatment of neuropathic pain

Novel dual-target FAAH and TRPV1 ligands as potential pharmacotherapeutics for pain management

Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain

Optimization of 4-arylthiophene-3-carboxylic acid derivatives as inhibitors of ANO1: Lead optimization studies toward their analgesic efficacy for inflammatory pain

Therapeutic Effects of Combined Treatment with the AEA Hydrolysis Inhibitor PF04457845 and the Substrate Selective COX-2 Inhibitor LM4131 in the Mouse Model of Neuropathic Pain

Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative

Analgesic Activities of the Mixed Opioid and NPFF Receptors Agonist DN-9 in a Mouse Model of Formalin-Induced Orofacial Inflammatory Pain.

Small molecule targeting NaV1.7 via inhibition of CRMP2-Ubc9 interaction reduces pain-related outcomes in a rodent osteoarthritic model

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

Discovery, Structure–Activity Relationship, and Mechanistic Studies of 1-((3 R ,4 S )-3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one as a Novel Potent Analgesic

Potent multitarget FAAH-COX inhibitors: Design and structure-activity relationship studies

Dual Inhibition of FAAH and MAGL Counteracts Migraine-like Pain and Behavior in an Animal Model of Migraine

Novel trifluoromethyl ketone derivatives as oral cPLA2/COX-2 dual inhibitors for resolution of inflammation in rheumatoid arthritis

Development of Tetrahydroquinoline-Based Inhibitors for Chronic Pain

Targeting the soluble epoxide hydrolase pathway as a novel therapeutic approach for the treatment of pain

A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain